Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Santen seeks FDA approval of levofloxacin for bacterial conjunctivitis

March 1, 2000

Allergan and Dura enter commercialization agreement for multiple products

Feb. 25, 2000

GenVec licenses gene for treating blindness

Feb. 24, 2000

Oxigene to develop CA4P for eye, skin and joint disorders

Feb. 23, 2000

New selectin inhibitor SKK-60060 shows promise in treatment of uveitis

Feb. 22, 2000

Blockade of VEGF alone is sufficient to prevent blinding illness

Feb. 21, 2000

Novel Merck compounds inhibit KDR kinase and VEGF activity

Feb. 15, 2000

Ophthalmic antibacterial on the way to market in Japan

Feb. 15, 2000

FDA issues approvable letter for Visudyne

Feb. 14, 2000

New ophthalmic gene licensed by InSite

Feb. 10, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...